The BoD of Swedish company Coegin Pharma AB (COEGIN:Nordic GM) has decided to raise 25,3 mSEK through a combination of a preferential rights issue and a new issue. The funds will be used for further strategic development of several projects in Coegin's portfolio of subsidiary companies.

Coegin Pharma raises 25 mSEK

The company, currently conducting a phase I/II trial with lead candidate AVX001 in actinic keratosis and preclinical development of AVX420 in leukemia and chronic kidney diseaese. Through the merger Coegin strengthens its drug development portfolio by putting strong focus on diabetes complications.

Coegin Pharma merges with Follicum

Coegin Pharma AS develops a new therapeutic approach to modulate cPLA levels in patients with certain forms of cancer and Chronic Kidney Disease.

Coegin pharma

Latest news about Coegin pharma

Coegin Pharma raises 25 mSEK

Coegin Pharma merges with Follicum